You searched for "intravitreal"

466 results found

Two-year results of a T&E aflibercept regime in caucasian PNV

This a retrospective study examining two-year outcomes of patients with pachychoroid neovasculopathy (PNV) treated with a treat and extend (T&E) regimen of intravitreal aflibercept. The mean age was 63.84 ± 7.92 years with nine males (35%) and 17 females (65%)....

Subfoveal choroidal thickness and PCV

This report studies the prognostic factors for visual improvement and the need for additional treatments at one year after the initial combination therapy of intravitreal ranibizumab injection or intravitreal aflibercept injection followed by PDT in eyes with PCV. Fifty-six eyes...

Combined ranibizumab and ablative therapy for Coat’s disease

The aim of this study was to observe the efficacy of intravitreal ranibizumab (IVR) combined with laser photocoagulation or cryotherapy, for Coats’ disease. Patients younger than 16 years of age who were diagnosed with Coats’ disease were included in this...

Features of AMD treatment non-responders

This is a retrospective consecutive case series of 365 eyes with age-related macular degeneration (AMD) who had three monthly intravitreal aflibercept treatments for at least 12 months. Responders were defined as complete resolution of exudation, intraretinal oedema, subretinal fluid, pigment...

Managing cataract surgery in a patient with diabetic maculopathy

A 56-year-old type 2 diabetic with previously treated bilateral diabetic maculopathy develops a cataract requiring surgery in the right eye. He has had grid laser previously, followed intermittently by intravitreal triamcinalone, Avastin and more recently Lucentis in both eyes. His...

VEGF and axial length (RVU)

The authors of this paper set out to examine whether the concentrations of VEGF in the vitreous were associated with refractive error and axial length in eyes without retinal disease, except of macular holes or epiretinal membranes. A vitreous sample...

Aflibercept for the treatment of neovascular glaucoma

The aim of this study was to investigate initial results regarding the treatment of neovascular glaucoma (NVG) with intravitreal aflibercept. NVG is classified into stages 0-3. In stages 1 and 2, abnormal vessel proliferation is seen with or without elevated...

Management of diabetic macular oedema in vitrectomised eyes

Diabetic macular oedema (DMO) is one of the leading causes of blindness; its prevalence is on the rise with progressive increase in numbers of people suffering from diabetes. The management of DMO has evolved significantly over the past few years....

Radiation maculopathy

This is a retrospective non-randomised study of 13 consecutive eyes of 13 patients affected by radiation maculopathy secondary to eye irradiation for primary uveal melanoma (Iodine-125 brachytherapy). All patients were treated with a single intravitreal 0.7mg dexamethasone implant and full...

IOP measures after intraocular chemotherapy

This study aimed to describe the relationship between intravitreal chemotherapy and IOP in children with retinoblastoma and identify risk factors for pronounced elevations. This was a retrospective study of ten cases (ten eyes) with 17 encounters overall. Mean age was...

Results of fixed aflibercept treatment regime in type 3 neovascularisation

In this prospective study the authors evaluate the effect of intravitreal aflibercept injections in the treatment of naive type 3 neovascularisation using a fixed treatment regime. Fourteen eyes of 14 patients were studied. All patients were treated with intravitreal 2.0...

A Multidisciplinary Approach to Neovascular Glaucoma in a Patient with Waldenström’s macroglobulinemia

An 84-year-old Caucasian male attended eye casualty with a four month history of reduced vision, a dull ache and photophobia in both eyes. He had also reported dizziness, weakness and intermittent epistaxis in the nine months prior to presentation. There...